Blaze Bioscience, a Seattle-based biotech that’s developing “tumor paint” to help surgeons differentiate healthy tissue from tumors that should be removed, has raised a $16.1 million Series B-1 round of funding from existing investors, according a regulatory filing and the company’s CEO. The funds are being used to complete work on the company’s early-stage clinical […]